RxDoctor Payments Data

Marcelo Rivera, MD

Internal Medicine · Poway, CANPI 1942311311

Payments from drug & device makers

$44,174in general payments, 2019–2025

Across 47 payments — averaging $939.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$44K
  • AstraZeneca$125
  • Lilly USA, LLC$124
  • Si-bone, Inc.$30
  • Hologic Sales And Service, LLC$27
  • Astellas Pharma US Inc$23
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$369100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,174 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$83,039
Medicare patients
162
Services billed
492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin72$99,880
EliquisApixaban82$96,821
JanuviaSitagliptin Phosphate59$67,531
TrulicityDulaglutide26$35,149
Bydureon BciseExenatide Microspheres12$28,893
OzempicSemaglutide20$26,966
RybelsusSemaglutide16$21,768
KeppraLevetiracetam12$12,574
TradjentaLinagliptin15$11,335
Breo ElliptaFluticasone/Vilanterol18$7,223
AuryxiaFerric Citrate12$6,915
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,779
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,633
Atorvastatin Calcium356$3,491
Rosuvastatin Calcium195$3,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$21$48,73336 claims
Lilly USA, LLCTrulicity$124$35,14926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Poway

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →